CFM
ALNY icon

Catalyst Funds Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Catalyst Funds Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-8,320
Closed -$3.79M – 341
2025
Q3 		$3.79M Sell
8,320
-2,450
-23% -$998K 0.57% 31
2025
Q2 		$3.51M Sell
10,770
-8,430
-44% -$2.33M 0.97% 15
2025
Q1 		$5.18M Buy
+19,200
New +$4.93M 1.36% 8

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Catalyst Funds Management's ALNY Position: Q4 2025 in Review

Catalyst Funds Management sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2025, closing a stake of 8,320 shares — an estimated $3.79M sold.

Catalyst Funds Management first reported a position in ALNY in Q1 2025 and held it in 3 quarters. The position peaked at $5.18M in Q1 2025. 848 funds tracked by Wall St. Rank hold ALNY as of Q4 2025.

  • Catalyst Funds Management reported no remaining Alnylam Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Catalyst Funds Management sold 8,320 Alnylam Pharmaceuticals shares in Q4 2025, an estimated $3.79M.
  • Catalyst Funds Management first reported a position in Alnylam Pharmaceuticals in Q1 2025 and held it in 3 quarters.
  • Catalyst Funds Management's Alnylam Pharmaceuticals position peaked at $5.18M in Q1 2025.
  • 848 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2025.

Based on Catalyst Funds Management's 13F filing for Q4 2025, filed 9 Feb 2026.